The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1455
Obinutuzumab (Gazyva) for Chronic Lymphocytic Leukemia (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Obinutuzumab (Gazyva – Genentech), a humanized anti-CD20 monoclonal antibody, has been approved by the FDA for use in combination with chlorambucil (Leukeran) in patients with previously untreated chronic lymphocytic leukemia (CLL). Two other anti-CD20 antibodies, rituximab (Rituxan) and ofatumumab (Arzerra),1 were previously approved for treatment of CLL.

STANDARD TREATMENT — Initial treatment of advanced or symptomatic CLL usually includes fludarabine, rituximab, and cyclophosphamide (Cytoxan, and others).2 Combining rituximab or ofatumumab with the alkylating agent chlorambucil has been effective in elderly patients and in those with coexisting medical conditions, who often have difficulty tolerating chemotherapy.

Ibrutinib (Imbruvica), an oral inhibitor of Bruton's tyrosine ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Obinutuzumab (Gazyva) for Chronic Lymphocytic Leukemia (online only)
Article code: 1455d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian